Deutsche PhysiologischeGesellschaft 19.-21.09.2024 Wien, Abstractbook C 01-04, p199-200 Neumann J, Hofmann B, Gergs U (2024c) Positive inotropic effects of glucose-dependent insulinotropic polypeptide in the human atrium.Naunyn-Schmiedebergs Arch Pharmacol (in revision) Neumann J, Hofmann B, Gergs U (2024d) Tirzepatide increased force in the isolated human atrium
Advantages of Injectable GLP-1 Drugs# Higher Peak Efficacy# Injectable formulations currently deliver higher peak weight loss: Best injectable: Tirzepatide at 20.9% (72 wk), retatrutide at 28.7% (68 wk) Best oral: Oral semaglutide 50 mg at 15.1% (68 wk), aleniglipron at 15.3% (36 wk, placebo-adjusted) For patients seeking maximum weight loss, injectables remain the more potent option as of early 2026
Gahl WA, Thoene J, Schneider J (2001) Cystinosis: a disorder of lysosomal membrane transport
The mechanism of action does not directly involve the coagulation cascade or platelet function, which has led to questions about whether these medications might influence thrombotic risk
Daily Dose: 2.33 mg (equivalent to 10 units / 0.10 mL), maintained throughout the full cycle Frequency: Administer once daily via subcutaneous injection, ideally at the same time each day Cycle Duration: 4-16 weeks of continuous use, followed by a 24 week break to assess response and support receptor recovery Injection Volume: Approximately 0.10 mL per dose, well within typical comfort limits for subcutaneous delivery (generally under 1.01.5 mL) Syringe Guidance: A 0.3 mL (30-unit) U-100 insulin syringe is recommended for improved accuracy when measuring small volumes Storage Instructions Proper storage is essential to maintain peptide stability and integrity
Weight loss is a known side effect for some patients taking bupropion, which led to its investigation as a weight management tool
.png)
.png)
